Mode
Text Size
Log in / Sign up

Seraph Microbind filter used in a 7-year-old with refractory septic shock and invasive Streptococcus pyogenes infectionNew Filter May Save Children in Life-Threatening Shock

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note potential adjunctive rescue role of hemoperfusion in refractory septic shock, but recognize severe ischemia risks and inability to establish causality.

A single case report from pediatric intensive care units details the use of Seraph Microbind 100 Microbind affinity blood filter in a previously healthy 7-year-old girl. The patient presented with refractory septic shock, streptococcal toxic shock syndrome, and invasive Streptococcus pyogenes infection. Standard therapy included broad-spectrum antibiotics, immunoglobulins, vasopressors, mechanical ventilation, and continuous renal replacement therapy.

The intervention involved the Seraph Microbind 100 Microbind affinity blood filter (pathogen-binding hemoperfusion). Main results showed progressive reduction in vasoactive support and improvement in metabolic parameters. The patient did not require venous-arterial extracorporeal membrane oxygenation and survived the clinical course. However, early severe peripheral ischemia occurred, leading to bilateral lower-limb amputations.

Safety concerns included early severe peripheral ischemia resulting in bilateral lower-limb amputations. Discontinuations were not reported, and tolerability was not reported. Key limitations include the inability to establish causality, the single-case nature of the report, and circuit instability requiring a stand-alone session. The study phase and publication type were not reported.

Practice relevance suggests a potential role for hemoperfusion as an adjunctive rescue therapy in selected cases. Causality cannot be established, and optimal timing, clinical efficacy in pediatric populations, and safety remain uncertain based on this evidence.

Septic shock is a dangerous state. The body reacts too strongly to germs. It damages organs fast. Many children do not survive this. Current treatments do not always work. Families face a terrifying wait for answers. This condition kills many young patients.

When Standard Care Fails

Doctors usually rely on antibiotics to kill bacteria. They use machines to help breathing or kidneys. But some infections are too strong. The body goes into a spiral of failure. This is called refractory shock. It means standard drugs stop working.

The Surprising Shift

This new approach changes how we treat blood. Instead of just drugs, we filter the blood itself. It removes the harmful parts directly. This targets the cause of the damage. It offers a physical way to clean the system.

Think of the blood like a dirty river. Germs and toxins flow through it. The filter acts like a giant sponge. It catches the bad stuff while letting good blood pass. This helps the body heal faster. The device uses special beads to grab toxins. It pulls them out of the flow.

The Study Snapshot

Researchers tested this on one seven-year-old girl. She was in the hospital for days. Her condition was getting worse despite all help. Treatment started 42 hours after admission. They ran the machine for four hours. She was already on many other machines.

After using the filter, her blood pressure improved. Her body started clearing waste better. She did not need the strongest heart support. Doctors saw her levels drop in two days. This suggests the filter helped stabilize her. Her heart stopped needing so much help.

This doesn’t mean this treatment is available yet.

The Hard Truth

She survived, but the story has a heavy cost. Severe blood flow issues caused damage to her legs. She needed amputations to stay alive. This shows the infection was very severe. The filter saved her life, but the damage was done.

Doctors say this is a promising sign. It shows the machine can work in real life. But one case is not enough proof. We need to see if it helps others. It might be a rescue option for some.

Parents should not expect this in every hospital. It is still an experimental rescue tool. Talk to your care team about options. Do not try to find this on your own. It is not a standard treatment yet.

We do not know if it works for everyone. The study only looked at one child. Other factors might have helped her recover. It was a last resort choice. We cannot say it caused the survival.

Scientists plan more studies to check safety. They want to find the best time to use it. Approval takes time to ensure it is safe for all. More data is needed before wide use.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundSeptic shock remains a major cause of morbidity and mortality in pediatric intensive care units, particularly in refractory cases unresponsive to standard therapy. Invasive Streptococcus pyogenes infection can lead to streptococcal toxic shock syndrome, characterized by severe inflammatory dysregulation and rapid clinical deterioration. Extracorporeal blood purification therapies, such as pathogen-binding hemoperfusion, have emerged as potential adjunctive treatments.Case PresentationWe report the compassionate use of the Seraph® 100 Microbind® affinity blood filter in a previously healthy 7-year-old girl with refractory septic shock caused by invasive S. pyogenes. Despite early initiation of broad-spectrum antibiotics, immunoglobulins, vasopressors, mechanical ventilation, and continuous renal replacement therapy, the patient developed severe multiorgan dysfunction and persistent hemodynamic instability. Hemoperfusion was initiated 42 h after pediatric intensive care unit admission. Due to circuit instability, treatment was performed as a stand-alone 4-h session. Following hemoperfusion, a progressive reduction in vasoactive support and improvement in metabolic parameters, including lactate clearance, were observed within 24–48 h. The patient stabilized without requiring veno-arterial extracorporeal membrane oxygenation. However, early severe peripheral ischemia led to bilateral lower-limb amputations. The patient survived and was discharged after prolonged hospitalization.ConclusionIn this case, pathogen-binding hemoperfusion with the Seraph® 100 filter was technically feasible and temporally associated with hemodynamic and metabolic improvement in refractory pediatric septic shock. Although causality cannot be established, these findings suggest a potential role for hemoperfusion as an adjunctive rescue therapy in selected cases. Further prospective studies are needed to determine its safety, optimal timing, and clinical efficacy in pediatric populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.